Creative Medical Technology Holdings Inc's Comment on Sales, Marketing and Customers
In October 2025, the company launched the BioDefense Veterans Initiative, a national program addressing long-term effects of toxic burn pit exposure among U.S. service members. It partnered exclusively with Greenstone Biosciences, Inc. for AI and induced pluripotent stem cell (iPSC) development to analyze cellular data from exposed service members and develop predictive models and regenerative therapies. The company invested capital in Bionance, which in turn invested in Applife Digital Solutions, Inc. The company completed patient enrollment in the ADAPT clinical trial evaluating CELZ-201 (Olastrocel) and progressed to follow-up and data analysis phases. It sold shares to institutional investors and issued warrants through offerings facilitated by Roth Capital Partners. In March and October 2025, the company entered into warrant exercise inducement agreements with holders of existing warrants to facilitate warrant exercises and issuance of new warrants.
News about Creative Medical Technology Holdings Inc Contracts
PHOENIX, July 2025 Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology firm focused on regenerative medicine, has announced significant developments in the prevention and treatment of Type 1 Diabetes (T1D) and in the field of AI-driven medical diagnostic programs.On July 17, 2025, the company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application d Prevention and/or Treatment of Type 1 Diabetes by Augmentation of Myeloid Suppressor Cell Activity . This patent aims to bolster the company’s ongoing research efforts in utilizing modulated immune cells to manage and potentially prevent T1D. The breakthrough sugg...
Creative Medical Technology Announces Breakthrough in iPSCelz Program: Successful Generation of Human Insulin-Producing Islet CellsCreative Medical Technology Holdings, a prominent biotechnology company specializing in regenerative approaches to immunotherapy, urology, neurology, and orthopedics, has recently achieved a remarkable development in its iPSCelz program. The company proudly announced the successful generation of human-induced pluripotent stem cells (iPSC)-derived Islet Cells, capable of producing human insulin. This groundbreaking achievement brings new hope for the treatment of diabetes and offers potential solutions to the challenges faced by patients worldwide.The current standard treatment f...
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a leading biotechnology company specializing in regenerative approaches to various medical fields, recently released a corporate update in connection with the filing of its Form 10-K on March 22, 2024. The company has achieved significant milestones over the past year, making it one of the most impactful periods in Creative Medical Technology s history.Revolutionizing Immunotherapy, Endocrinology, Urology, Gynecology, and OrthopedicsCreative Medical Technology Holdings has dedicated its efforts to revolutionizing healthcare through regenerative approaches. By harnessing the power of regenerative medicine, the company aims to address critical medical ...
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a renowned player in biotech innovation, has made a significant breakthrough in the battle against Type 1 Diabetes Mellitus (T1D). Recently, the company has gained FDA authorization for an expanded access therapy that utilizes CELZ-201, a pioneering cell-based program, aimed at managing abnormal glucose tolerance and preventing T1D in individuals at high risk. This ground-breaking therapy holds immense potential in preventing the onset of T1D and is set to revolutionize the field of diabetes prevention and management.Understanding Type 1 Diabetes Mellitus:Type 1 Diabetes Mellitus is a chronic autoimmune condition where the body s immune system mistak...
Creative Medical Technology Holdings Inc’s Comment on Sales, Marketing and Customers
In October 2025, the company launched the BioDefense Veterans Initiative, a national program addressing long-term effects of toxic burn pit exposure among U.S. service members. It partnered exclusively with Greenstone Biosciences, Inc. for AI and induced pluripotent stem cell (iPSC) development to analyze cellular data from exposed service members and develop predictive models and regenerative therapies. The company invested capital in Bionance, which in turn invested in Applife Digital Solutions, Inc. The company completed patient enrollment in the ADAPT clinical trial evaluating CELZ-201 (Olastrocel) and progressed to follow-up and data analysis phases. It sold shares to institutional investors and issued warrants through offerings facilitated by Roth Capital Partners. In March and October 2025, the company entered into warrant exercise inducement agreements with holders of existing warrants to facilitate warrant exercises and issuance of new warrants.
Sources:
Creative Medical Technology Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Creative Medical Technology Holdings Inc’s corporate clients.
For your research, we’ve provided 9 tables on Creative Medical Technology Holdings Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
